Boehringer, Zealand reframe diabetes pact

Share this article:

Boehringer Ingeleim and Zealand Pharma are still diabetes partners but have redefined the relationship they began in 2011.

The companies said in a joint statement that they will continue to collaborate on novel glucagon/GLP-1 dual agonists for diabetes or obesity, but ZP2929 is no longer the keystone compound.

Instead, Zealand gets all rights to ZP2929, and another agent will be swapped in. The companies said the original financial collaboration arrangements are staying put.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.